Sp2tx

SP2 Therapeutics is redefining peptide synthesis, addressing core biopharmaceutical production challenges. Our patent-protected FLOWSMART system combines Nobel-prize winning solid phase peptide synthesis with AI-guided, resin-based flow chemistry, achieving massive cost savings and scalability. SP2 Therapeutics is a spinout from Seoul National University's renowned Institute of Molecular Biology and Genetics. Our core team’s expertise spans diverse domains such as resin-based chemistry, bioinformatics, engineering, and machine learning. Our FLOWSMART synthesis platform can greatly accelerate your peptide drug development efforts.